Literature DB >> 19786821

Tetracycline actions relevant to rosacea treatment.

H C Korting1, C Schöllmann.   

Abstract

Until today, the pathogenesis of rosacea is not known in detail. Yet in recent years evidence has been accumulating that rosacea with its common symptoms such as inflammatory lesions, erythema, telangiectasia, phymatous changes, and ocular symptoms is of inflammatory nature. Tetracycline derivatives like doxycycline successfully used in the treatment of skin diseases like acne and rosacea seem to inhibit different inflammatory pathways involved in the pathogenesis by various modes of action. Although data for skin diseases are relatively scanty, the following modes of action of tetracyclines seem to be most relevant for an effective treatment of acne and rosacea: inhibition of matrix metalloproteinases, downmodulation of cytokines, inhibition of cell movement and proliferation, inhibition of granuloma formation, inhibition of reactive oxygen species, nitric oxide, and angiogenesis, whereas inhibition of phospholipase A2 seems to be of lower importance. The role of the saprophytic mite Demodex folliculorum remains to be clarified. Additional studies are necessary to further elucidate how tetracyclines work in rosacea treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786821     DOI: 10.1159/000235550

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  16 in total

Review 1.  Rosacea: The cytokine and chemokine network.

Authors:  Peter Arne Gerber; Bettina Alexandra Buhren; Martin Steinhoff; Bernhard Homey
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

Review 2.  Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit.

Authors:  Aimee M Two; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-01

Review 3.  Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature.

Authors:  Michael O Griffin; Eduardo Fricovsky; Guillermo Ceballos; Francisco Villarreal
Journal:  Am J Physiol Cell Physiol       Date:  2010-06-30       Impact factor: 4.249

Review 4.  Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2017-09-01

5.  Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

6.  Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

7.  Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline.

Authors:  Aysegul Arman; Duriye Deniz Demirseren; Tamer Takmaz
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

Review 8.  Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.

Authors:  Iva Markulin; Marija Matasin; Viktorija Erdeljic Turk; Melita Salković-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2022-01-04       Impact factor: 3.850

9.  [Systemic therapy of rosacea].

Authors:  M Schaller; K Belge
Journal:  Hautarzt       Date:  2013-07       Impact factor: 0.751

10.  Rosacea: New Concepts in Classification and Treatment.

Authors:  Esther J van Zuuren; Bernd W M Arents; Mireille M D van der Linden; Sofieke Vermeulen; Zbys Fedorowicz; Jerry Tan
Journal:  Am J Clin Dermatol       Date:  2021-03-23       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.